Diabetes Therapies for Dementia

Moran, Chris; Callisaya, Michele L.; Srikanth, Velandai; Arvanitakis, Zoe

doi:10.1007/s11910-019-0973-4

Cited by 20 publications

(12 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although epidemiological evidence indicates that diabetes mellitus, obesity, and hypertension increase the risk of dementia, remission of cardiometabolic risk factors through medical treatment failed to ameliorate cognitive decline in patients, as shown by several large and prospective clinical trials. 21 , 22 , 23 , 24 In these trials, patients had higher cardiovascular risk and multiple complications, thus cardiovascular outcomes were a primary end point and cognitive function was a secondary end point. GLP‐1 RAs are a new class of hypoglycemic drug that can stimulate insulin release, reduce glucagon release, slow gastric emptying, and induce satiety.…”

Section: Discussionmentioning

confidence: 99%

Activation of Glucagon‐Like Peptide‐1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism‐Independent Pathway

Jia

Yan

et al. 2021

JAHA

View full text Add to dashboard Cite

Background Patients with hypertension and diabetes mellitus are susceptible to dementia, but regular therapy fails to reduce the risk of dementia. Glucagon‐like peptide‐1 receptor agonists have neuroprotective effects in experimental studies. We aimed to assess the effect of liraglutide, a glucagon‐like peptide‐1 receptor agonist, on cognitive function and whether its effect was associated with metabolic changes in patients with type 2 diabetes mellitus. Methods and Results Fifty patients with type 2 diabetes mellitus were recruited in this prospective study. All patients underwent cognitive assessment and brain activation monitoring by functional near‐infrared spectroscopy. At 12 weeks, patients in the glucagon‐like peptide‐1 group acquired better scores in all cognitive tests and showed remarkable improvement in memory and attention ( P =0.040) test compared with the control group after multivariable adjustment. Compared with the control group, liraglutide significantly increased activation of the dorsolateral prefrontal cortex and orbitofrontal cortex brain regions ( P =0.0038). After liraglutide treatment, cognitive scores were significantly correlated with changes in these activating brain regions ( P <0.05), but no correlation was observed between the changes in cognitive function and changes of body mass index, blood pressure, and glycemic levels. Conclusions We concluded that liraglutide improves cognitive decline in patients with type 2 diabetes mellitus. This beneficial effect is independent of its hypoglycemic effect and weight loss. The optimal intervention should be targeted to cognitive decline in the early stages of dementia. Registration URL: https://www.ClinicalTrials.gov ; Unique identifier: NCT03707171.

show abstract

Section: Discussionmentioning

confidence: 99%

Activation of Glucagon‐Like Peptide‐1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism‐Independent Pathway

Jia

Yan

et al. 2021

JAHA

View full text Add to dashboard Cite

show abstract

“…2). Growing evidence suggests that both AD and VaD are associated with diabetes [7,8,15,16,215,216], and the risk of dementia development could be reduced by successful intervention of diabetes and its comorbidities [13,215,217]. As summarized in previous review articles, berberine is a promising antidiabetic agent [20,21,24,163], and preclinical evidence suggests that berberine has neuroprotective effects [25,[218][219][220][221].…”

Section: Limitations and Future Perspectivesmentioning

confidence: 99%

Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review

Shinjyo

Parkinson

Bell

et al. 2020

Journal of Integrative Medicine

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…T2DM is a recognized risk factor for dementia. T2DM and Dementia have some common underlying pathophysiologies, which makes people interested in the reuse of therapeutic drugs for type 2 diabetes, which is beneficial to brain health (Moran et al, 2019 ). In dementia, there is a progressive deterioration of functional and cognitive abilities, eventually causing a heavy burden on health and social services.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of intranasal insulin in improving cognition in mild cognitive impairment or dementia: a systematic review and meta-analysis

Long

Han

Yang

et al. 2022

Front. Aging Neurosci.

View full text Add to dashboard Cite

BackgroundInsulin regulates many aspects of brain function related to mild cognitive impairment (MCI) or dementia, which can be delivered to the brain center via intranasal (IN) devices. Some small, single-site studies indicated that intranasal insulin can enhance memory in patients with MCI or dementia. The pathophysiology of Alzheimer's disease (AD) and diabetes mellitus (DM) overlap, making insulin an attractive therapy for people suffering from MCI or dementia.ObjectiveThe goal of the study is to evaluate the effectiveness of IN insulin on cognition in patients with MCI or dementia.MethodsWe searched the electronic database for randomized controlled trials (RCTs) that verified the effects of insulin on patients with MCI or dementia.16 studies (899 patients) were identified.ResultsThe pooled standard mean difference (SMD) showed no significant difference between IN insulin and placebo groups; however, statistical results suggested a difference between study groups in the effects of ADCS-ADL; AD patients with APOE4 (-) also showed improved performance in verbal memory; other cognitions did not improve significantly.ConclusionIn view of IN insulin's promising potential, more researches should be conducted at a larger dose after proper selection of insulin types and patients.Systematic review registrationhttp://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022353546.

show abstract

Diabetes Therapies for Dementia

Cited by 20 publications

References 62 publications

Activation of Glucagon‐Like Peptide‐1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism‐Independent Pathway

Activation of Glucagon‐Like Peptide‐1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism‐Independent Pathway

Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review

Efficacy of intranasal insulin in improving cognition in mild cognitive impairment or dementia: a systematic review and meta-analysis

Contact Info

Product

Resources

About